PBR Nachrichten

 

Under the agreement, Insilico will lead efforts using AI to identify molecules that meet predefined scientific and early development criteria. Takeda will take the lead in advancing selected The post Insilico Medicine, Takeda partner on AI-driven drug discovery appeared first on Pharmaceutical Business review....

The deal includes a strategic equity investment by AimedBio in Inocras and a joint research agreement between the two companies. Additionally, the whole genome sequencing (WGS) capabilities of The post Inocras, AimedBio team up for cancer treatments appeared first on Pharmaceutical Business review....

This decision was issued in a Complete Response Letter (CRL) which cited deficiencies at a third-party manufacturing facility producing OLC. The FDA did not raise concerns related to The post US FDA rejects approval of Unicycive's kidney disease therapy appeared first on Pharmaceutical Business review....

Under this agreement, Innovent will handle the marketing, distribution and promotion of the product within the region, while Eli Lilly will continue to manage manufacturing, supply and development. Verzenios The post Eli Lilly and Innovent agree Verzenios commercialisation deal in China appeared first on Pharmaceutical Business review....

The MOIP has issued Patent Number 10-2960889, providing protection for Anixa's breast cancer vaccine approach in South Korea through 2040. This specific composition-of-matter patent is exclusively licensed from The post Anixa Biosciences secures Korean patent for breast cancer vaccine appeared first on Pharmaceutical Business review....

Under the terms of the deal, Theravance Biopharma shareholders will receive $17 per share. Shareholders will also receive a contingent value right (CVR) entitling them to 80% of The post Zymeworks agrees to buy Theravance Biopharma for $929m appeared first on Pharmaceutical Business review....

The FDA has requested further information, primarily focusing on the manufacturing control strategy of the biological component of NASP and on deficiencies related to contract manufacturing facilities. It The post FDA issues complete response letter to Sobi's NASP for gout appeared first on Pharmaceutical Business review....

This Jaypirca CHMP recommendation for CLL applies across all lines of therapy, regardless of previous Bruton tyrosine kinase (BTK) inhibitor treatment. Following this recommendation, the Jaypirca application moves The post Lilly's Jaypirca receives CHMP positive opinion for CLL in Europe appeared first on Pharmaceutical Business review....

The initial phase of the partnership, valued at up to $15m and running until 2027, may be expanded if scientific milestones are met and both parties agree. The The post Immunai and Boehringer partner to identify T-cell targets appeared first on Pharmaceutical Business review....

Ionis will retain the responsibility for commercialising the RNA-targeted medicine within the US and will remain the global lead for development activities. Under the agreement, Recordati will handle regulatory The post Ionis grants Recordati rights to zilganersen for Alexander disease appeared first on Pharmaceutical Business review....

The authorisation applies to adults with resectable MIBC who cannot be treated with cisplatin-based chemotherapy. It makes the combination the first regimen that pairs a programmed death-1 (PD-1) The post MSD's Keytruda-Padcev combo secures EC approval for MIBC appeared first on Pharmaceutical Business review....

Frazier Life Sciences led the financing round along with new investors EQT Life Sciences, Forbion, Monograph and Wellington Management. LifeArc Ventures, Oxford Science Enterprises and the University of The post RQ Bio secures $115m to develop influenza antibody programme appeared first on Pharmaceutical Business review....

The partnership will combine Combotope's SMART-Phage discovery platform with Boehringer Ingelheim's research and development capabilities, focusing on multiple identified oncology targets. Combotope CEO Ola Blixt said: “At Combotope, The post Boehringer and Combotope partner for cancer antibodies appeared first on Pharmaceutical Business review....

Nuvectis secured worldwide rights, outside specified Asian territories, to develop, manufacture and commercialise Haisco's drug candidates HSK42360 and HSK39297. Haisco will receive $40m in upfront and near-term payments, The post Haisco and Nuvectis sign licensing deal for two drugs appeared first on Pharmaceutical Business review....

This expands intellectual property protection already in place for Genprex in jurisdictions such as China, Europe, Japan, Russia and the US. Genprex's Reqorsa is currently in development alongside The post Genprex's Reqorsa combo secures Canadian patent for lung cancer appeared first on Pharmaceutical Business review....

The partnership will combine BioArctic's BrainTransporter technology with an unidentified Lilly drug candidate. BioArctic is set to receive a $30m upfront payment. If the new product progresses successfully, The post Lilly and BioArctic sign deal to develop neurodegenerative therapy appeared first on Pharmaceutical Business review....

According to a regulatory filing, Sun Pharma will buy the entire issued and outstanding share capital of Innovcare Lifesciences via a cash transaction. The company expects to close The post Sun Pharma to acquire Innovcare Lifesciences for $28.7m appeared first on Pharmaceutical Business review....

The approval follows a positive finding in the pivotal IRAKLIA Phase III study, which demonstrated non-inferior efficacy and pharmacokinetics compared with the intravenous (IV) formulation. It also marks The post Japan approves Sanofi's Sarclisa combo for MM treatment appeared first on Pharmaceutical Business review....

The partnership will bring together Voro Therapeutics' tumour-activated biologics platform with Alloy Therapeutics' cluster of differentiation 3 (CD3) antibodies and multispecific engineering capabilities. This joint effort aims to The post Voro and Alloy partner on tumour-selective TCE therapeutics appeared first on Pharmaceutical Business review....

The deal value comprises an upfront payment and further payments tied to the achievement of future clinical and regulatory milestones. The proposed acquisition will add several anti-inflammatory candidates The post Biogen to acquire RayThera for up to $1bn appeared first on Pharmaceutical Business review....